BioLife Solutions, Inc. (BLFS) has been on a downward spiral lately with significant selling pressure. After declining 17.6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a m ...

We add real-time buy and sell signals on these, as well as other trading opportunities which we provide in our active chat community. We look at companies with a defensible competitive advantage and the opportunity and/or business models which have the potential to generate considerable operational leverage.If you are interested in similarly small, high-growth potential stocks you could join us at our marketplace service SHU Growth Portfolio , where we maintain a portfolio and a watchlist of similar stocks. ...

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 11% over the past four weeks, closing at $24.2, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $32.67, representing a 35% upside [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1, where the lowest estimate is $31.00 (28.1% increase) and the highest is $34.00 (40.5% increase) [2] - A smaller standard deviation indicates greater agreement among analysts regarding price targets, which is crucial for understanding the variability of estimates [2][9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher for BLFS, which is a positive indicator for potential stock upside [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.9% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be wise due to historical inaccuracies in predicting stock price movements [3][10]

BioLife Solutions (NasdaqCM:BLFS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAnna Snopkowski - Equity Research AssociateRoderick de Greef - Chairman and CEOTroy Wichterman - CFOConference Call ParticipantsBrendan Smith - Director, Life Science & Diagnostic Tools and Biotech AnalystCarl Byrnes - Managing Director, Senior Research AnalystMacae Etoch - Equity Research AnalystMatt Hewett - Senior Research AnalystMatt Stanton - Equity Research AnalystMichael Okunewitch - Senior Resea ...

BioLife Solutions (NasdaqCM:BLFS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAnna Snopkowski - Equity Research AssociateRoderick de Greef - Chairman and CEOTroy Wichterman - CFOConference Call ParticipantsBrendan Smith - Director, Life Science & Diagnostic Tools and Biotech AnalystCarl Byrnes - Managing Director, Senior Research AnalystMacason Etok - Equity Research AnalystMatt Hewitt - Senior Research AnalystMatt Stanton - Equity Research AnalystMichael Okunewitch - Senior Rese ...

BioLife Solutions (NasdaqCM:BLFS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker7Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q4 2025 Shareholder and Analyst Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead.Speaker9Tha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporat ...

Financial Performance - BioLife Solutions, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year ended December 31, 2025[4]. - The report does not provide specific revenue figures or growth percentages in the available content[4]. Compliance and Reporting - The report was filed on January 12, 2026, indicating the company's compliance with the Securities Exchange Act of 1934[4]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. - The financial results will not be deemed "filed" under the Exchange Act, limiting liability under Section 18[5]. - The Chief Financial Officer, Troy Wichterman, signed the report, indicating executive oversight[10]. Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BLFS[2]. - The company operates from its headquarters located at 3303 Monte Villa Parkway, Bothell, WA[2]. Additional Information - The press release detailing the financial results is attached as Exhibit 99.1[6]. - No information on new products, technologies, market expansion, or mergers and acquisitions was provided in the current report[4].

Core Viewpoint - BioLife Solutions, Inc. is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, along with a business update [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company provides solutions that maintain the health and function of biologic materials during various stages including collection, development, storage, and distribution [1] Financial Reporting - The financial results will be discussed in a conference call and live webcast scheduled for 4:30 PM ET (1:30 PM PT) on the release date [1] - Access to the webcast will be available through the Investor Relations page of the BioLife Solutions website [1] Contact Information - The Chief Financial Officer, Troy Wichterman, can be contacted for media and investor relations inquiries [1]

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market [Accessibility Statement] Skip NavigationBOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- [BioLife Solutions, Inc.](NASDAQ: [BLFS]), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain c ...